false0001294133Inogen Inc00012941332026-11-162026-11-16

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

INOGEN, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36309

33-0989359

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

500 Cummings Center

Suite 2800

 

Beverly, Massachusetts

 

01915

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (805) 562-0500

 

 

 

 

(Former address)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

INGN

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Kevin R.M. Smith Separation Agreement; Resignation as a Director

As previously reported in the Current Report on Form 8-K filed by Inogen, Inc. (the “Company”), on November 5, 2026, Kevin R.M. Smith’s role as an officer and employee of the Company ended effective October 30, 2026 (the “Separation Date”). In connection with the separation of Mr. Smith’s employment with the Company, on November 16, 2026, Mr. Smith and the Company entered into a separation agreement and release related to the termination of Mr. Smith’s employment with the Company (the “Separation Agreement”).

The Separation Agreement provides that, subject to (a) Mr. Smith’s execution of the Separation Agreement, (b) the Separation Agreement becoming effective and (c) Mr. Smith’s continued compliance with the terms of the Separation Agreement, the Company will provide Mr. Smith with severance benefits consistent with those set forth in Mr. Smith’s Employment and Severance Agreement with the Company, effective as of November 10, 2023. The Separation Agreement also provides for Mr. Smith’s eligibility to earn a prorated annual bonus for fiscal 2026 based on actual performance and the vesting of certain equity awards that were scheduled to vest on December 1, 2026.

Also in connection with the separation of his employment with the Company and the entry into the Separation Agreement, Mr. Smith resigned from the Company’s board of directors (the "Board"), effective as of November 16, 2026. Mr. Smith’s resignation was not the result of any disagreement with the Company relating to the Company’s operations, policies or practices. Following Mr. Smith’s resignation, the Board reduced the authorized number of directors from nine to eight, effective as of November 17, 2026.

The summary of the Separation Agreement set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed with this Current Report on Form 8-K as Exhibit 10.1 and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The exhibits listed below are furnished or filed, as applicable, with this Current Report on Form 8-K:

 

Exhibit

 

 Description

10.1

 

Separation Agreement and Release by and between the Company and Kevin R.M. Smith, dated November 16, 2026.

104

The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

INOGEN, INC.

 

 

 

 

Date:

November 19, 2026

By:

/s/ Jason Richardson

 

 

 

Jason Richardson
Executive Vice President, Chief Financial Officer
Treasurer (Principal Accounting and Financial Officer)